Home › Compare › LTGHY vs ABBV
LTGHY yields 4.73% · ABBV yields 3.06%● Live data
📍 LTGHY pulled ahead of the other in Year 1
Combined, LTGHY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LTGHY + ABBV for your $10,000?
Life Healthcare Group Holdings Limited, together with its subsidiaries, operates private hospitals in South Africa, Canada, the United Kingdom, rest of Europe, and Internationally. It operates through two segments, Hospitals and Complementary Services; and Healthcare Services. The company provides range of acute hospitals and complementary services; Life Esidimeni services, such as chronic mental healthcare, frail care rehabilitation, step-down care, correctional services, and primary healthcare and substance abuse recovery programs; and life employee health solutions, including on-site occupational and primary healthcare services and employee wellness programs. It also offers services in the areas of diagnostics, mental health, acute rehabilitation, renal dialysis, oncology, cardiology, neurology, orthopedic, pediatric, dermatology, ophthalmology, gynecology, and obstetric. In addition, the company provides diagnostic imaging services; magnetic resonance imaging and computerized tomography scanners; develops, manufactures, and distributes radiopharmaceuticals for use in positron emission tomography-computerized tomography (PET-CT) diagnostics. The company was formerly known as Afrox Healthcare Limited and changed its name to Life Healthcare Group Holdings Limited in January 2005. Life Healthcare Group Holdings Limited was founded in 1983 and is headquartered in Johannesburg, South Africa.
Full LTGHY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.